Drug Safety Alliance to Advocate Pharmacovigilance at Global Convention

CEO Cathy Stokes to Lead Discussion at Drug Information Association`s 45th
Annual Meeting
RESEARCH TRIANGLE PARK, N.C.--(Business Wire)--
Drug Safety Alliance (DSA), a global leader in pharmaceutical safety and
pharmacovigilance, announced that CEO Cathy Stokes will moderate a panel
discussion at the Drug Information Association`s (DIA`s)45th Annual Meeting on
Tuesday, June 23, 2009 in San Diego, CA. Stokes will be joined by Dr. Elizabeth
Garrard, DSA`s expert on safety signal detection, for the session
"Pharmacovigilance on a Budget".

The DIA Annual Meeting is the biopharmaceutical industry's largest, longest
running, best-value, global, multidisciplinary event. This year`s program offers
learning opportunities for everyone and features the biggest names from
industry, regulatory and academia.

"Drug safety is a critical and vital function necessary to protect the public
health. Although much is talked about and written regarding what is needed and
how to do it, little is available on the cost/benefit analyses and budgeting for
the drug safety function," said Drug Safety Alliance`s CEO Cathy Stokes. "This
session will examine how to approach the issue and how to prepare a plan to
perform excellent drug safety within a reasonable cost structure. Physicians,
nurses, pharmacists, regulators, and others will understand where costing issues
arise for the industry, vendors, and health care professionals."

"The panel discussion will include current and projected requirements for a
company to perform drug safety both pre-clinically and for marketed products
when profitability and company financial health are priorities as well as
maintaining best practices in patient safety," said Dr. Elizabeth Garrard. "We
will also define the necessary requirements and dive fully into discussions of
added value functions that provide your company the insurance of building a most
comprehensive safety program."

About Drug Safety Alliance

Founded in 2000, Drug Safety Alliance (DSA) provides pharmacovigilance expertise
to large and small pharmaceutical and biotechnology companies to ensure and
improve patient safety. DSA's mission is to partner with clients to mitigate
their drug safety risks and to maximize product longevity and value. Driven by
the highest ethical standards, DSA is uniquely focused to provide high-quality
pre- and post-market drug safety services including adverse event case
management, risk management, global regulatory compliance, and safety database
hosting and support. DSA is headquartered in the Research Triangle Park region
of North Carolina with strategic partnerships worldwide. For more information
please visit www.DrugSafetyAlliance.com.

About the Drug Information Association (DIA)

DIA serves more than 30,000 biopharmaceutical professionals from industry,
academia, and regulatory agencies worldwide. Through its domestic and
international meetings, training courses, workshops and webinars, DIA provides a
neutral global forum for the exchange of information critical to the advancement
of the drug discovery and lifecycle management processes. Headquartered in
Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai,
India, and Beijing, China, the Association is led by its volunteer-based Board
of Directors and executive management team. For more information, visit
www.diahome.orgor call 215-442-6100.

Catalyst Communications
Lynne Beaman, 919-606-1380
lynne.beaman@catalystcom.us
or
Drug Safety Alliance:
Deena Wegner, 919-401-8003

Copyright Business Wire 2009